GlassScriptPhysician profile
Benjamin G Carter
NPI 1093919912
$2,090.42
in general payments reported to CMS, 2019-2025
23 companies · $717 in 2025
The $717 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $164 · 2021: $21.84 · 2022: $167 · 2023: $310 · 2024: $374 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,361 · Education: $39.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,361.35 |
| Education | $39.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $656.70 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Pfizer INC. | $256.15 | 2019-2023 | |
| Biofrontera INC. | $181.16 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ucb, INC. | $167.52 | 2021-2025 | Bimzelx |
| Revance Therapeutics, INC. | $121.78 | 2025 | Daxxify |
| Lilly USA, LLC | $93.95 | 2020-2025 | Ebglyss, Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $79.45 | 2022-2024 | Odomzo, Blu-U |
| Prugen, INC. Pharmaceuticals | $74.00 | 2019-2020 | |
| Janssen Biotech, INC. | $67.36 | 2023-2024 | Tremfya, Stelara, Simponi |
| Celgene Corporation | $58.06 | 2019 | |
| Galderma Laboratories, L.P. | $57.83 | 2025 | Nemluvio |
| Amgen INC. | $50.38 | 2020 | |
| Leo Pharma INC. | $37.56 | 2022-2024 | Adbry |
| Dermavant Sciences, INC. | $34.94 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $29.46 | 2023-2025 | Zoryve |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $20.54 | 2023 | Libtayo |
| Mimedx Group, INC. | $19.91 | 2024 | |
| Organon LLC | $15.13 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.79 | 2019 | |
| Blueprint Medicines Corporation | $14.23 | 2023 | |
| Vyne Pharmaceuticals INC. | $13.70 | 2020 | |
| Merck Sharp & Dohme LLC | $13.19 | 2019 | |
| Allergan, INC. | $12.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.